• Outlook Therapeutics is trading 5.5% up at $1.05 as it extends recovery following the FDA approval of its wet AMD therapy, LYTENAVA.
  • The stock is building on a 10.62% gain from July 29, 2026, further supported by recent insider buying activity.
  • Director Faisal Sukhtian purchased 95,398 shares on July 29, 2026, indicating a vote of confidence in the company's prospects.